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HBVAbstract Introduction: Angiogenesis is known to play a pivotal role in most of malignancy,
including HCC, and in chronic inﬂammation.
Aim: To investigate the angiogenic output in HCV and HBV infection and its implication in the
development of HCV associated HCC.
Materials and methods: Blood samples were collected and grouped as; HS healthy subjects control
group; HCC–HCV; chronic HCV infected patient group (HCV+ve) who are positive for serum
anti-HCV antibodies and HCV–RNA; anti-HCV antibody positive and HCV–RNA negative
patient group (HCVve); patients with positive HBsAg and HBV-DNA group (HBV+ve); and
HBsAg positive and HBV-DNA negative patient group (HBVve). Serum levels of vascular endo-
thelial growth factor, angiopoietin-2, endostatin and angiostatin were assessed in different studied
groups.
236 M.A. Abdel Mohsen et al.Results: The level of sVEGF was insigniﬁcantly elevated in both HCV+ve and HCVve groups
when compared with controls, while Ang-2, sES and sAS were signiﬁcantly elevated in both groups
as compared with healthy controls. The studied parameters were signiﬁcantly elevated in HBV-+ve
patients when compared with the control. However, HBVve patients showed signiﬁcantly elevated
levels in sAng-2, sES and sAS when compared with the control while the level of sVEGF was equal
to that of controls. In patients with HCC, the studied parameters showed a signiﬁcant elevation
when compared with healthy controls and patients either with HBV or HCV infection except for
sAS in the case of HCV-+ve patients and VEGF for HBV-+ve patients who were also higher
but not signiﬁcant.
Conclusion: The increased hepatic angiogenesis in chronic HCV and HBV could provide the
molecular basis for liver carcinogenesis and contribute to the increased risk of HCC in patients with
cirrhosis due to HCV and/or HBV.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Hepatocellular carcinoma (HCC) comprises nearly 6% of all
incident cancer cases worldwide, with the overwhelming major-
ity occurring in the developing world.1 With more than half a
million new cases each year, HCC is the ﬁfth most common
tumor worldwide and the third cause of cancer-related deaths.2
Chronic infection with HBV and HCV has been cited as by far
the most important etiologic agent.3 Annual incidence of HCC
in patients with cirrhosis due to HBV infection exceeds 2%, and
in those with cirrhosis due to HCV infection, it is estimated
between 3% and 8%. Association of the two viruses or chronic
exposure to alcohol substantially increases these ﬁgures.4
In Egypt, the increasing importance of HCV infection in
the etiology of HCC has been shown, now estimated to
account for 40–50% of cases.5 On the other hand, the preva-
lence of HBsAg in Egypt is of intermediate endimicity (2–
8%). Nearly 2–3 million Egyptians are chronic carriers of
HBV.6 It appears that the cause of HBV-associated HCC is
a combination of HBV-encoded oncogenic activities along
with the synergistic effect of chronic inﬂammation.7
Angiogenesis is known to play a pivotal role in almost every
kind of malignancy favoring growth and metastasis of several
types of cancer including HCC,8 and in chronic inﬂammation,
where, accumulation of the inﬂammatory inﬁltrate and the
development of ﬁbrosis increases resistance of the tissue to
blood ﬂow and delivery of oxygen, resulting in hypoxia.9
Tumor angiogenesis is a complex phenomenon and is regu-
lated by a net balance between the proponents and the inhib-
itors of the process.10
The difference in the pathogenesis between chronic HBV and
HCV viral infection and their progression into HCC may be a
consequence of the angiogenic processes. Accordingly, the aim
was to investigate the angiogenic output in HCV and HBV
infection and its implication in the progression into HCC. The
objective is approached by assessing the serum levels of pro-
angiogenic parameters; endothelial growth factor (VEGF),
angiopoitein-2 (Angio-2) and anti-angiogenic parameters; endo-
statin (ES) and angiostatin (AS) as. The presence or absence of
the active replicating virus was taken in consideration.2. Materials and methods
This work included 100 patients admitted to the Hepatology
Units, Medical Research Institute and Faculty of Medicine,
Alexandria University in addition to 20 healthy volunteers
with no evidence of liver disease and negative for both HCV
and HBV. None of the patients had a history of alcohol abuse
or previous interferon treatment. The study was approved by
the local Ethics Committees of the Medical Research Institute
and Faculty of Medicine, Alexandria University. A signed
informed consent was obtained from all the participants in
the present study.
The study enrolled six groups; (1) healthy subjects (HS)
group; (2) HCC–HCV patient group; (3) chronic HCV infected
patient group (HCV+ve) who are positive for serum anti-
HCV antibodies and HCV–RNA; (4) anti-HCV antibody posi-
tive and HCV–RNA negative patient group (HCVve); (5)
patients with positive HBsAg and HBV–DNA group
(HBV+ve); and (6) HBsAg positive HBV-DNA negative
patient group (HBVve).
Originally, the study was designed to enroll HCC cases
associated with HBV, and HCC cases with no previous history
of HBV or HCV infection (spontaneous HCC) but unfortu-
nately those cases were hard to ﬁnd. However, HCC patients
enrolled in the present study have no previous history of other
malignant diseases. Eighty percent of those patients were at
stage II/III. Also, careful subsequent exclusion of any patient
with a possible alternative cause of chronic liver disease was
considered.
Venous blood samples were collected and sera separated
and stored at 20 C until used. Serum samples were tested
for anti-HCV Ab and HBsAg according to the manufacturer’s
instructions (EIA; Abbott GmbH, Delkenheim, Germany).
Quantitative detection of HCV-RNA and HBV-DNA was car-
ried out by real time PCR.11
Serum level of VEGF was determined using Bender Med-
systems GMBH ELISA Kits, Vienna, Austria, Europe. Serum
levels of Agiopoietin-2 (Angio-2), endostatin (ES) and angio-
statin (AS) were determined using RayBio Human ELISA
kits Raybiotech, Inc.
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SPSS 11.5 statistical package (SPSS Inc., Chicago, IL, USA)
was used for data analysis. MannWhitneyU test was used after
examining the signiﬁcance of Kruskal–WallisH test (p< 0.05).
The p values of less than 0.008 were considered statistically sig-
niﬁcant according to Bonferroni adjustment. Correlations were
explored using Spearman correlation coefﬁcient (p< 0.05).
3. Results
3.1. HCV patients
The mean values of VEGF in HCV+ve and HCVve were
insigniﬁcantly different from that in healthy control subjects
p= 0.114 and 0.461, respectively (Table 1). Meanwhile, the
mean levels of sAng-2, sES and sAS were signiﬁcantly elevated
in HCV+ve and HCVve patients when compared to that in
the healthy control subjects p= 0.0001 (Tables 1 and 2).
The mean values of sVEGF, sAng-2 and sAS in HCV+ve
patients were insigniﬁcantly different from that in HCVve
patients p= 0.583, 0.102 and 0.060, respectively (Tables 1
and 2), while, the mean level of sES in HCV+ve patients
was signiﬁcantly lower from that in HCVve patients
p= 0.0001 (Tables 1 and 2).
3.2. HBV patients
The mean levels of sVEGF, sAng-2, sES and sAS in HBV+ve
patients were signiﬁcantly higher than the healthy control sub-
jects (p= 0.001 and 0.0001) (Tables 1 and 2). In HBVve
patients, the mean levels of sVEGF showed to be insigniﬁ-
cantly different from that in healthy control subjects
p= 0.968 (Table 1), while the mean levels of sAng-2, sES
and sAS showed a signiﬁcant elevation p= 0.0001 (Tables 1
and 2). It should be noted that the mean levels of all angiogenic
markers in HBV+ve patients were signiﬁcantly higher than
those in HBVve patients p= 0.0001 and 0.004, except for
sAS which was high but not signiﬁcant p= 0.242.
While the mean levels of sVEGF and sES in HBV+ve were
signiﬁcantly higher than those in HCV+ve p= 0.0001 (TablesTable 1 Serum levels of proangiogenic factors, VEGF and Angio-2
HS HCC HCV (+ve)
VEGF Angio-2 VEGF Angio-2 VEGF Ang
Min. 126 234 219 10,750 118 1170
Max. 388 958 1196 37,186 706 19,9
X 245 470 649 16,620 229 9925
±S.E. 21 48 66 1388 38 907
p1 0.0001* 0.0001* 0.114 0.00
p2 0.0001* 0.00
p3
p4
p1: Comparison against healthy subject (HS) group.
p2: Comparison against hepatocellular carcinoma (HCC) group.
p3: Comparison against HCV (+ve) group.
p4: Comparison against HBV (ve) group.
* p value was considered signiﬁcant at level <0.008.1 and 2), however, Ang-2 and As showed insigniﬁcant differ-
ence p= 0.127 and 0.023, respectively (Tables 1 and 2). Mean-
while, the mean levels of sVEGF and sES in HBVve patients
were insigniﬁcant different from those in HCVve patients
p= 0.718 and 0.013, respectively (Tables 1 and 2). While the
mean level of sAng-2 and sAS in HCVve patients was signif-
icantly lower than that in HBVve patients, p= 0.003 and
0.0001, respectively (Tables 1 and 2).
3.3. HCC patients
A highly signiﬁcant increase in the mean levels of pro- and
anti-angiogenic factors were noticed when compared to that
in healthy subjects, p= 0.0001, (Tables 1 and 2) and to that
in HCV+ve patients p= 0.0001, except sAS was high but
not signiﬁcant p= 0.277 (Table 2). Moreover, serum levels
of sVEGF, sAng-2, sES and sAS were signiﬁcantly higher in
HCC patients than that in HBV+ve patients p= 0.003 and
0.0001, except sVEGF was high but not signiﬁcant p= 0.017
(Tables 1 and 2).
3.4. Bio-statistical correlation
Data of the present study showed that sVEGF is signiﬁcantly
correlated with sAng-1; r= 0.48, p= 0.0001, sES; r= 0.60,
p= 0.0001, and sAS; r= 0.29, p= 0.0001, in a positive man-
ner (Fig. 1a–c). Also, sES was found to be signiﬁcantly corre-
lated positively with sAng-2; r= 0.62, p= 0.0001, and sAS;
r= 0.41, p= 0.0001, in a positive manner (Fig. 2a and b).
Finally, the data showed a signiﬁcant positive correlation
between sAng-2 and sAS; r= 0.43, p= 0.0001 (Fig. 3).
4. Discussion
The formation of ﬁbrotic septa and capillarization of sinusoids
due to deposition of ﬁbrillar extracellular matrix (ECM) in the
space of disease, result in an increase in resistance to blood
ﬂow and oxygen delivery.12 These are premises for hypoxia
and the transcription of hypoxia-sensitive proangiogenic
genes.13 Moreover, the mediators of inﬂammatory response
in chronic liver diseases may stimulate other cells in the(pg/ml), mean ± S.E., in the different studied groups.
HCV (ve) HBV (+ve) HBV (ve)
io-2 VEGF Angio-2 VEGF Angio-2 VEGF Angio-2
117 6795 202 8624 157 2333
56 479 12,744 1038 21,310 305 10,699
243 9498 451 12147 237 7127
27 364 50 736 13 558
01* 0.461 0.0001* 0.001* 0.0001* 0.968 0.0001*
01* 0.0170 0.003*
0.583 0.102 0.0001* 0.127
0.718 0.003* 0.0001* 0.0001*
Table 2 Serum levels of anti-angiogenic factor, ES and AS (pg/ml), mean ± S.E., in the different studied groups.
HS HCC HCV (+ve) HCV (ve) HBV (+ve) HBV (ve)
ES AS ES AS ES AS ES AS ES AS ES AS
Min. 0.05 17.5 68.1 28.6 1.4 38.4 4.8 54.0 11.8 19.6 2.0 42.2
Max. 1.9 75.5 116.2 840 13.2 234.2 13.2 203.3 42.6 361.3 27.5 83.8
X 0.68 36.7 90.1 207.9 4.72 129.9 9.6 97.3 24.3 94.8 15.3 ± 64.6
±S.E. 0.09 4.6 2.93 40.0 0.64 12.4 0.55 9.3 2.22 17.8 1.70 4.1
p1 0.0001* 0.0001* 0.0001* 0.0001* 0.0001* 0.0001* 0.0001* 0.0001* 0.0001* 0.0001*
p2 0.0001* 0.2270 0.0001* 0.0001*
p3 0.0001* 0.0600 0.0001* 0.023
p4 0.0130 0.0001* 0.004* 0.242
p1: Comparison against healthy subject (HS) group.
p2: Comparison against hepatocellular carcinoma (HCC) group.
p3: Comparison against HCV (+ve) group.
p4: Comparison against HBV (ve) group.
* p value was considered signiﬁcant at level <0.008.
Figure 1 Overall correlation of sVEGF with (a) sAng-2, (b) sES and (c) sAS.
238 M.A. Abdel Mohsen et al.surrounding microenvironment to express other pro-angio-
genic factors to sustain angiogenesis.14 Vespasiani–Gentilucci
et al.,2 demonstrated that in chronic HCV patients signiﬁcant
increased levels of Ang-2 and equivalent VEGF levels with
respect to controls were seen. Also, they reported an associa-
tion of the stage of ﬁbrosis with sAng-2 levels. These were in
agreement with results of the present study where HCV+ve
and HCVve patients showed signiﬁcantly increased levels
of sAng-2 and equivalent VEGF levels with respect to con-
trols. The insigniﬁcant elevated level of sVEGF could be
attributed to signiﬁcant elevation in levels of both endostatin
and angiostatin, which have been reported to down-regulate
the production of sVEGF.15 This in turn, may reﬂect the role
of Ang-2 in enhancement of angiogenesis that is associated
with HCV infection.
A signiﬁcant elevation in both sAS and sES levels in
HCV+ve and HCVve patients was observed when com-
pared to that in control. Notably, an insigniﬁcant difference
was shown in sVEGF, sAng-2 and sAS levels in HCV+ve
patients when compared to that in HCVve patients. Thus,
the absence of signiﬁcance in those angiogenic markers maybe explained by the fact that just the attack of the HCV may
initiate the process of angiogenesis. This can be supported by
Hoare et al.,16 who reported that ﬁbrosis was observed in liver
biopsy of nonviremic HCV antibody-positive patients which
was similar to the inﬂammatory inﬁltrate in viremic cases.
They have suggested the observed immune response in the
liver, supporting the view that HCV may persist in the liver
in the majority of HCV RNA-negative cases.
On the other hand, HBV encoded proteins as HBx protein
which stabilizes and facilitates the transactivation function of
the hypoxia inducible factor-1a17,18 which regulates the expres-
sion of multiple genes involved in angiogenesis such as VEGF.
VEGF could also account for the induction of Ang-2 observed
in chronic hepatitis B, contributing to pathological angiogene-
sis and hepatocellular carcinoma progression.19 These could be
the molecular basis that may explain the signiﬁcant elevation
in sVEGF and sAng-2 levels in HBV+ve group. In HBV+ve
infection, the signiﬁcant elevation in endostatin and angio-
statin levels could be an attempt to counteract the action of
signiﬁcantly elevated levels of pro-angiogenic factors. In
HBVve patients, an insigniﬁcant elevation in the level of
Figure 2 Overall correlation of sES with (a) sAng-2, and (b) sAS.
Figure 3 Overall correlation of sAng-2 with sAS.
Angiogenic output in viral hepatitis and hepatocellular carcinoma 239sVEGF and a signiﬁcant elevation in sAng-2 were observed.
Meanwhile, the levels of sES and sAS were signiﬁcantly ele-
vated in those patients. The initiation of angiogenic response
in those carrier HBV patients could be attributed to the pro-
duction of HBx protein very early after infection which medi-
ates the establishment and maintenance of the chronic carrier
state.20The virulent nature of HCV might explain the observation
that sVEGF and sES levels in HBV+ve patients were signiﬁ-
cantly higher than those in HCV+ve patients while Ang-2
level was insigniﬁcantly raised.21 Unlike previously stated,
these observations indicate that angiogenesis is particularly
linked to HBV infection, suggesting a possible contribution
to HBV-related liver oncogenesis (Tables 1 and 2).22
It has been reported that the expression pattern of Ang-2
is strongly associated with the expression of VEGF in the
process of tumor angiogenesis, and subsequently, in tumor
progression.23 In agreement with previous study,24 signiﬁ-
cantly elevated levels of sVEGF and sAng-2 were expected
in HCC patients. It was suggested that sAng-2 may allow ves-
sels to be more responsive to sprouting signals provided by
VEGF.25 It was revealed that over expression of Ang-2 blocks
Ang-1 mediated Tie receptor signaling and causes loss of the
tight vascular structure, which results in the exposure of endo-
thelial cells to VEGF.26 These ﬁndings may suggest that an
advantageous environment for angiogenesis may be created
by the HCC itself, secreting not only VEGF but also Ang-
2. Accordingly, angiostatic response is not tumor-speciﬁc,
but is a consequence of angiogenic normal regulatory mecha-
nisms that couple pro and anti-angiogenic signaling to the
induction of an opposing response. This obligatory coupling
of pro- and anti-angiogenic signaling is advantageous since
excessive angiogenesis is associated with a variety of disease
states14 and uncontrolled angiogenesis would compromise
normal tissue architecture in growth, morphogenesis, and
wound healing.27 It was reported that s-ES level was signiﬁ-
cantly higher in HCC patients and has a signiﬁcantly inverse
correlation with the angiogenic score of HCC.20 Also, it was
conﬁrmed that the source of s-endostatin is the tumor. In our
study, sES and sAS levels were signiﬁcantly higher in the
HCC group than all other included groups. However, it is still
controversial that endostatin expression or its serum level has
a signiﬁcant role in predicting the prognosis of patients with
HCC.20,25
240 M.A. Abdel Mohsen et al.Thus, in HCC, the elevated anti-angiogenic markers could
be attributed to the fact that tumor hypoxia produced a
homeostatic feedback up-regulation of VEGF since its expres-
sion is believed to be modulated by hypoxia. In addition,
angiostatin is generated through the action of matrix metallo-
proteinases (MMP), that are activated by proangiogenic sig-
naling cascades such as hypoxia inducible factor induction,
to oppose the angiogenic response.20 As a result, the release
of anti-angiogenic factors may explain the control exerted by
primary tumors over metastasis.28
The sequence of pathological insult of the liver in viral
infection usually starts with inﬂammation; cirrhosis till the
end stage of HCC may necessitate more pro/anti-angiogenic
output. This may explain the elevation levels of the studied
parameters in the HCC group when compared with HCV+ve
patients in particular and HBV+ve patients in general.
In conclusion, there is a difference in angiogenic/anti-angio-
genic outputs between HBV and HCV infection and HCC
development. The increased hepatic angiogenesis in chronic
HCV and HBV could provide the molecular basis for liver car-
cinogenesis and contribute to the increased risk of HCC in
patients with cirrhosis due to HCV and/or HBV. Furthermore,
anti-angiogenic therapeutic agents should be targeted to coun-
teract the action of proangiogenic factors rather than enhance-
ment of antiangiogenic factors.
Conﬂict of interest
We have no conﬂict of interest to declare.References
1. Lehman EM, Wilson ML. Epidemiology of hepatitis viruses
among hepatocellular carcinoma cases and healthy people in
Egypt: a systematic review and meta-analysis. Int J Cancer
2009;124:690–7.
2. Vespasiani-Gentilucci U, Galati G, Mazzarelli C, D’Avola D,
Spataro S, Gallo P, et al. Angiogenic cytokines in patients
undergoing antiviral treatment for chronic hepatitis C virus
infection. J Interferon Cytokine Res 2011;31:207–10.
3. Barazani Y, Hiatt JR, Tong MJ, Busuttil RW. Chronic viral
hepatitis and hepatocellular carcinoma. World J Surg
2007;31:1243–8.
4. Semela D, Dufour JF. Angiogenesis and hepatocellular carci-
noma. J Hepatol 2004;41:864–80.
5. El-Zayadi AR, Badran HM, Barakat EM, Attia Mel D, Shawky S,
Mohamed MK, et al. Hepatocellular carcinoma in Egypt: a single
center study over a decade.World J Gastroenterol 2005;11:5193–8.
6. El-Zayadi A, Hepatitis B. Virus infection: the Egyptian situation.
Arab J Gastroenterol 2007;8:94–8.
7. Margaret EMD, Karl M. Viruses associated with human cancer.
Biochim Biophys Acta 2008;1782:127–50.
8. Mazzanti R, Messerini L, Comin CE, Fedeli L, Ganne`-Carrie N,
Beaugrand M. Liver angiogenesis as a risk factor for hepatocel-
lular carcinoma development in hepatitis C virus cirrhotic
patients. World J Gastroenterol 2007;13(37):5009–14.
9. Amarapurkar AD, Vibhav DN, Patel ND. Angiogenesis in
chronic liver disease. Ann Hepatol 2007;6(3):170–3.10. Ramanujan S, Koenig GC, Padera TP, Stoll BR, Jain RK. Local
imbalance of proangiogenic and antiangiogenic factors: a potential
mechanism of focal necrosis and dormancy in tumors. Cancer Res
2000;60:1442–8.
11. Mitsunaga S, Fujimura K, Matsumoto C, Shiozawa R, Hirakawa
K, Nakajima K, et al. High-throughput HBV DNA and HCV
RNA detection system using a nucleic acid puriﬁcation robot and
real time detection PCR: its application to analysis post transcrip-
tion hepatitis. Transfusion 2002;42:100–6.
12. Friedman SL. Mechanisms of hepatic ﬁbrogenesis. Gastroenterol-
ogy 2008;134:1655–69.
13. Copple BL, Bustamante JJ, Welch TP, Kim ND, Moon JO.
Hypoxia-inducible factor-dependent production of proﬁbrotic
mediators by hypoxic hepatocytes. Liver Int 2009;29:1010–21.
14. Carmeliet P. Angiogenesis in health and disease. Nat Med
2003;9:653–60.
15. Raymond E. Tumor angiogenesis inhibitors: media and scientiﬁc
aspects. Presse Med 1998;27:1221–4.
16. Hoare M, Gelson WTH, Rushbrook SM, Martin DM, Curran
T, Woodall T, et al. Histological changes in HCV antibody-
positive, HCV RNA-negative subjects suggest persistent virus
Infection. Hepatology 2008;48:1737–45.
17. Moon EJ, Jeong CH, Jeong JW, Kim KR, Yu DY, Murakami S,
et al. Hepatitis B virus X protein induces angiogenesis by
stabilizing hypoxia-inducible factor-1-alpha. FASEB J
2004;18:382–4.
18. Pichiule P, Chavez JC, La Manna JC. Hypoxic regulation of
angiopoietin-2 expression in endothelial cells. J Biol Chem
2004;279:12171–80.
19. Szab E, Paska C, Kaposi Novak P, Schaff Z, Kiss A. Similarities
and differences in hepatitis B and C virus induced hepatocarcino-
genesis. Pathol Oncol Res 2004;1:5–11.
20. Martin-Vilchez S, Lara-Pezzi E, Trapero-Maruga´n M, Moreno-
Otero R, Sanz-Cameno P. The molecular and pathophysiological
implications of hepatitis B X antigen in chronic hepatitis B virus
infection. Rev Med Virol 2011;21:315–29.
21. Dhar DK, Ono T, Yamanoi A, Soda Y, Yamaguchi E, Rahman
MA, et al. Serum endostatin predicts tumor vascularity in
hepatocellular carcinoma. Cancer 2002;95:2188–95.
22. Mazzanti R, Messerini L, Monsacchi L, Buzzelli G, Zignego AL,
Foschi M, et al. Chronic viral hepatitis induced by hepatitis C but
not hepatitis B virus infection correlates with increased liver
angiogenesis. Hepatology 1997;25:229–34.
23. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander
D, Zagzag D, et al. Vessel cooption, regression, and growth in
tumors mediated by angiopoietins and VEGF. Science
1999;284:1994–8.
24. Yamaguchi R, Yano H, Nakashima O, Akiba J, Nishida N,
Kurogi M, et al. Expression of vascular endothelial growth factor-
C in human hepatocellular carcinoma. J Gastroenterol Hepatol
2006;21:152–60.
25. Ferrara N. Vascular endothelial growth factor as a target for
anticancer therapy. Oncologist 2004;9:2–10.
26. Stratmann A, Risau W, Plate KH. Cell type-speciﬁc expression of
angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma
angiogenesis. Am J Pathol 1998;153:1459–66.
27. Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV. Angio-
statin’s molecular mechanism: aspects of speciﬁcity and regulation
elucidated. J Cell Biochem 2005;96:242–61.
28. Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F.
Angiogenesis and anti-angiogenesis in hepatocellular Carcinoma.
Cancer Treat Rev 2006;32:437–44.
